Integrated Diagnostics Holdings

IDHC · Main Market · Health Care · mcap £230m · 39.8p

Beta Briefing, track record and bull & bear case are not ready for Integrated Diagnostics Holdings yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 51 companies are already wired into a briefing: browse them.

Financials · LTM to 30 Jun 26

Source: results 11 Sep 26 ↗

Revenue: £139m
Operating profit: £39.1m
Net income: £23.2m
Free cash flow: £20.1m
Net cash: £19.6m
Market cap: £221m
EV / EBIT: 5.4×
FCF yield: +9.1%
Price / book: 3.1×

Latest half-year · H1 26 vs H1 25 results 11 Sep 26 ↗

Revenue: £71.7m
Operating profit: £19.6m
Net income: £12.1m
Cash from operations: £9.4m

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Income statement Cash flow Balance sheet

Annual Half-yearly

Latest report: H1 26 (six months to 30 Jun 26), published 11 Sep 26 · read the results ↗

£m unless stated · newest first · italic = calculated (LTM, H2 = FY − H1) · hover a value for its source

	LTM Jun 26	FY 25	FY 24
Revenue	138.6	121.2	102.1
Gross profit	60.0	51.7	39.0
Adjusted EBITDA	–	41.6	30.9
EBITDA	48.3	42.2	30.3
Operating profit	39.1	33.5	21.7
Depreciation (owned assets)	5.8	5.3	5.4
Depreciation (right-of-use)	3.1	3.1	3.1
Amortisation	0.4	0.4	0.2
Fair value gains / losses	(0.0)	(0.1)	(0.5)
Finance costs	(4.9)	(4.2)	(3.5)
Profit before tax	38.2	32.7	25.7
Tax	(14.5)	(12.6)	(7.7)
Net income (owners)	23.2	19.5	19.2
EPS basic	4.1p	3.4p	2.9p
EPS diluted	4.1p	3.4p	2.9p

	H1 26	vs H1 25	H2 25	H1 25
Revenue	71.7	+32%	67.0	54.2
Gross profit	31.1	+36%	28.9	22.8
EBITDA	24.3	+33%	24.0	18.2
Operating profit	19.6	+40%	19.6	13.9
Depreciation (owned assets)	3.0	+21%	2.8	2.5
Depreciation (right-of-use)	1.6	+6%	1.6	1.5
Amortisation	0.2	+19%	0.2	0.2
Fair value gains / losses	0.0	n/m	(0.0)	(0.1)
Finance costs	(2.2)	+44%	(2.7)	(1.5)
Profit before tax	19.5	+40%	18.7	14.0
Tax	(7.1)	+36%	(7.4)	(5.2)
Net income (owners)	12.1	+44%	11.0	8.4
EPS basic	2.2p	–	2.0p	1.4p
EPS diluted	2.2p	–	2.0p	1.4p

	LTM Jun 26	FY 25	FY 24
Cash from operations	32.7	29.4	28.0
Interest paid	(4.1)	(3.4)	(3.0)
Tax paid	(10.3)	(7.8)	(2.7)
Capex (PP&E)	(9.2)	(6.7)	(3.7)
Capex (intangibles)	(0.2)	(1.3)	(0.3)
Lease principal paid	(3.2)	(2.7)	(2.6)
Dividends paid	(11.8)	(8.3)	(0.5)
Share buybacks	–	–	(6.7)

	H1 26	vs H1 25	H2 25	H1 25
Cash from operations	9.4	+55%	23.3	6.0
Interest paid	(2.0)	+50%	(2.1)	(1.3)
Tax paid	(8.1)	+45%	(2.2)	(5.6)
Capex (PP&E)	(4.2)	+141%	(5.0)	(1.7)
Capex (intangibles)	(0.2)	−87%	(0.1)	(1.3)
Lease principal paid	(2.3)	+30%	(1.0)	(1.7)
Dividends paid	(3.6)	n/m	(8.2)	(0.0)

	Latest Jun 26	FY 25	FY 24
Property, plant & equipment	34.0	31.0	23.4
Inventories	10.5	6.6	5.0
Trade receivables	27.1	21.8	15.9
Cash	25.4	26.0	18.6
Current assets	67.7	61.5	48.3
Total assets	142.8	133.8	111.8
Trade payables	18.6	17.5	13.0
Borrowings, current	1.9	2.7	3.5
Current liabilities	40.6	42.0	33.9
Borrowings, non-current	3.9	3.9	0.6
Total liabilities	70.5	69.5	56.9
Non-controlling interests	12.1	11.6	12.4
Total equity	72.3	64.3	54.9
Net cash / (debt) ex leases	3.7	7.3	3.5
Net cash / (debt) incl. leases	–	7.3	3.5
Shares in issue	–	581.3m	–

	H1 26	Q Mar 26	H2 25	Q Sep 25	H2 24
Property, plant & equipment	34.0	–	31.0	–	23.4
Inventories	10.5	9.3	6.6	6.3	5.0
Trade receivables	27.1	–	21.8	–	15.9
Cash	25.4	–	26.0	28.3	18.6
Current assets	67.7	–	61.5	–	48.3
Total assets	142.8	–	133.8	–	111.8
Trade payables	18.6	10.1	17.5	–	13.0
Borrowings, current	1.9	–	2.7	–	3.5
Current liabilities	40.6	–	42.0	–	33.9
Borrowings, non-current	3.9	–	3.9	–	0.6
Total liabilities	70.5	–	69.5	–	56.9
Non-controlling interests	12.1	–	11.6	–	12.4
Total equity	72.3	–	64.3	–	54.9
Net cash / (debt) ex leases	3.7	–	7.3	–	3.5
Net cash / (debt) incl. leases	–	10.2	7.3	4.2	3.5
Shares in issue	–	–	581.3m	–	–

Line items extracted automatically from each results announcement; when a later report restates a period, the later figure is shown. LTM and H2 are calculated from reported periods. Check the source before relying on a figure.

Company filings. Not investment advice.